Literature DB >> 11701466

Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol.

T Sakai1, V S Kamanna, M L Kashyap.   

Abstract

Evidence indicates that the high density lipoprotein (HDL) subfraction containing apolipoprotein A-I without apolipoprotein AII (LP-AI) is more antiatherogenic than HDL particles containing apolipoprotein A-I and apolipoprotein A-II (LP-AI+AII). This study examined the effect of extended-release niacin (niacin-ER) and gemfibrozil on LP-AI and LP-AI+AII particles in patients with low levels of HDL cholesterol (HDL-C). Mechanisms by which these agents modulate HDL particles were investigated by in vitro studies using human hepatoblastoma (Hep G2) cells. A total of 139 patients with low HDL-C (</=40 mg/dL) were randomized to niacin-ER or gemfibrozil in a multicenter double-blind trial. Patients were dose-escalated with once-nightly niacin-ER (1 to 2 g) or gemfibrozil (1.2 g) for 19 weeks. Niacin-ER had a greater effect in raising HDL-C and apolipoprotein A-I levels than did gemfibrozil. Niacin-ER at 1- and 2-g doses increased LP-AI levels by 8.7+/-4.0% (P=0.033) and 24.0+/-4.4% (P<0.001), respectively. Gemfibrozil had no consistent effect on LP-AI levels. LP-AI+AII levels increased 5% to 8% by both agents. In vitro studies showed that niacin, but not gemfibrozil, selectively decreased the uptake of (125)I-labeled LP-AI holoparticles by Hep G2 cells. The uptake of [(3)H]cholesterol ester was approximately 75% greater from LP-AI versus LP-AI+AII particles, but neither niacin nor gemfibrozil affected cholesterol ester uptake. These data indicate that unlike gemfibrozil, niacin selectively increases LP-AI compared with LP-AI+AII particle concentration in patients with low HDL-C levels. The mechanism of action of increased LP-AI concentration appears to be mediated by decreased hepatic removal of LP-AI particles, which are more efficient in reverse cholesterol transport, thus suggesting an additional mechanism by which niacin mediates its antiatherogenic properties.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11701466     DOI: 10.1161/hq1001.096624

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  17 in total

Review 1.  Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events.

Authors:  Michael H Davidson
Journal:  Curr Atheroscler Rep       Date:  2003-09       Impact factor: 5.113

Review 2.  Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.

Authors:  Martin Hersberger; Arnold von Eckardstein
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 3.  Niacin for primary and secondary prevention of cardiovascular events.

Authors:  Stefan Schandelmaier; Matthias Briel; Ramon Saccilotto; Kelechi K Olu; Armon Arpagaus; Lars G Hemkens; Alain J Nordmann
Journal:  Cochrane Database Syst Rev       Date:  2017-06-14

4.  Niacin increases HDL biogenesis by enhancing DR4-dependent transcription of ABCA1 and lipidation of apolipoprotein A-I in HepG2 cells.

Authors:  Lin-Hua Zhang; Vaijinath S Kamanna; Shobha H Ganji; Xi-Ming Xiong; Moti L Kashyap
Journal:  J Lipid Res       Date:  2012-03-01       Impact factor: 5.922

Review 5.  New compounds able to control hepatic cholesterol metabolism: Is it possible to avoid statin treatment in aged people?

Authors:  Laura Trapani; Marco Segatto; Valentina Pallottini
Journal:  World J Hepatol       Date:  2013-12-27

Review 6.  Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia.

Authors:  Paul L McCormack; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 7.  Niacin, lipids, and heart disease.

Authors:  Shaista Malik; Moti L Kashyap
Journal:  Curr Cardiol Rep       Date:  2003-11       Impact factor: 2.931

Review 8.  Niacin: an old drug rejuvenated.

Authors:  Vaijinath S Kamanna; Shobha H Ganji; Moti L Kashyap
Journal:  Curr Atheroscler Rep       Date:  2009-01       Impact factor: 5.113

9.  beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice.

Authors:  Robert W Walters; Arun K Shukla; Jeffrey J Kovacs; Jonathan D Violin; Scott M DeWire; Christopher M Lam; J Ruthie Chen; Michael J Muehlbauer; Erin J Whalen; Robert J Lefkowitz
Journal:  J Clin Invest       Date:  2009-04-06       Impact factor: 14.808

Review 10.  The mechanism and mitigation of niacin-induced flushing.

Authors:  V S Kamanna; S H Ganji; M L Kashyap
Journal:  Int J Clin Pract       Date:  2009-09       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.